膀胱內攝護腺突起程度可預測男性膀胱過動症患者使用Mirabegron之治療效果
沈元琦、李偉嘉、王弘仁、莊燿吉
高雄長庚紀念醫院泌尿科
The degree of intravesical prostatic protrusion can predict the treatment response for male overactive bladder patients treated with Mirabegron
Yuan-Chi Shen、Wei-Chia Lee、Hung-Jen Wang、Yao-Chi Chuang
Department of Urology, Kaohsiung Chang Gung Memorial Hospital
Purpose: Overactive bladder (OAB) is a concomitant condition associated with BPO and intravesical prostatic protrusion (IPP) is a morphometric parameter associated with the degree of benign prostatic obstruction (BPO). Mirabegron, a selective b3 adrenoceptor agonist, is widely used for treatment of OAB. We aimed to evaluate the treatment response in male OAB patients with different degree of IPP.
Materials and Methods: We enrolled a consecutive cohort of 192 male LUTS patients ≥ 40 years in a tertiary referral center. The patients with OABSS urgency score of ≥2 and sum score of ≥3 was defined as the OAB group and treated with Mirabegron 50mg as the only initial medication. The therapeutic outcomes were assessed at baseline, 4, and 12 weeks in three different degree of IPP groups (0-5mm, 6-10 mm and more than 10mm).
Results: Mirabegron usage was associated with a statistically significant decrease in OABSS total score at 4-week (8.1 ± 2.5 to 6.2 ±2.7, p = 0.0036) and a further 10% decrease at 12-week in IPP 0-5mm group but insignificant in groups of IPP 6-10mm and >10mm. The sub-score of urgency, urge incontinence and nocturia was also significant decreased at 4-week in IPP 0-5mm group and insignificant in other two groups.
Conclusion: The degree of IPP ≦5mm can predict the satisfactory treatment response with Mirabegron 50mg in reducing OAB symptom , especially urgency, urge incontinence and nocturia for male patient.